Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07523711 · ClinicalTrials.gov registry record · Phase 1
Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity
A Phase 1 study, sponsored by Amgen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT07523711 is a Phase 1 study that is actively recruiting participants, run by Amgen. The registered enrollment target is 45 participants.
The verdict
NCT07523711, a Phase 1 study, is actively recruiting participants, sponsored by Amgen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
Interventions
- DRUG Maridebart Cafraglutide
- DRUG COC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2026-04-09 |
| Est. Completion | 2026-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07523711
The ClinicalTrials.gov registry entry for NCT07523711 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Maridebart Cafraglutide is the first listed.
NCT07523711 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07523711 about?
NCT07523711 is a clinical study titled "Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or Obesity". The primary objective of the trial is to evaluate the effect of maridebart cafraglutide on the pharmacokinetics (PK) of a combined oral contraceptive (COC) in postmenopausal female participants living with overweight or obesity.
What is the current status of trial NCT07523711?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2026-04-09. Estimated completion is 2026-11-18.
What interventions are being tested in trial NCT07523711?
The interventions under investigation include: Maridebart Cafraglutide (DRUG), COC (DRUG).
Who is sponsoring clinical trial NCT07523711?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.